P3 Health Partners (PIII) Jefferies 2024 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies 2024 Global Healthcare Conference summary
1 Feb, 2026Leadership and organizational background
CEO Aric Coffman joined in May, bringing extensive experience in value-based care and senior-focused healthcare.
The executive team includes seasoned leaders with backgrounds in Healthcare Partners and DaVita Medical Group.
Highlighted a physician-led management team with over 20 years of value-based care experience, emphasizing leadership stability and expertise.
The company operates in five states and 27 counties, with a strong presence on the West Coast and in Florida.
Partnerships span over 20 payers, both national and local, supporting market density and network stability.
Business model and operational approach
Manages 126,000 full-risk lives, 92% Medicare Advantage and 8% ACO REACH, and 11,000 ACO Reach lives.
Operates through full-risk contracts, aligning payers, providers, and patient outcomes.
High patient and provider retention rates, with 90% patient persistency and 97% PCP retention.
Utilizes data aggregation, risk stratification, and a proprietary tech platform to drive targeted care management and provider performance.
Technology partnerships, such as with Innovaccer, enhance analytics, predictive modeling, and AI capabilities.
Financial performance and growth
2023 revenue was $1.3 billion, with 2024 guidance between $1.45–$1.5 billion.
Reported FY 2023 revenue of $1.27B and medical margin of $135M.
Company-wide, membership grew 27% and revenue 42% from 2022 to Q1 2024.
Arizona market saw 308% Part C revenue growth and 238% membership increase from 2019 to Q1 2024.
Operating expenses reduced by almost 30% year-over-year, mainly in back office functions.
Latest events from P3 Health Partners
- 2026 outlook projects a $170M EBITDA improvement and 29,000 new Medicare Advantage members.PIII
Q4 202526 Mar 2026 - Operational focus and technology upgrades target margin growth and cash flow positivity by 2025.PIII
17th Annual LD Micro Main Event Conference13 Feb 2026 - Q2 revenue up 15% to $379M, but profitability declined and liquidity risks remain.PIII
Q2 20242 Feb 2026 - Tech-enabled value-based care and disciplined growth drive profitability and expansion.PIII
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Revenue up 26% year-over-year, but net loss widened and liquidity risks persist.PIII
Q3 202414 Jan 2026 - $130M+ turnaround and value-based care drive 2025 profitability and growth.PIII
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - 2024 revenue up 18% to $1.5B; 2025 guidance targets profitability despite wider net loss.PIII
Q4 202426 Dec 2025 - Registering 134.8M shares for resale, with proceeds from warrants to fund growth amid ongoing losses.PIII
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, auditor ratification, executive pay, and a major warrant issuance.PIII
Proxy Filing1 Dec 2025